Beam Therapeutics (BEAM) Strengthens Cash Position as Key Trials Move Forward
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best gene-editing stocks to buy according to hedge funds. On November 14, Beam Therapeutics Inc.
Beam Therapeutics Inc. (BEAM)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 11,038,834 | $267,912,511 | +25% | 1.59% |
| 2. | Farallon Capital Thomas Steyer | 10,063,111 | $244,231,704 | +1% | 1% |
| 3. | Kynam Capital Derrick Tang | 2,517,647 | $61,103,293 | +5% | 4.55% |
| 4. | Casdin Capital Eli Casdin | 1,600,000 | $38,832,000 | +11% | 3.24% |
| 5. | Contrarius Investment Management Stephen Mildenhall | 1,533,269 | $37,212,439 | 1.68% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.68 | 459 | $12,246.12 | 14 | 2025-10-27 | Filing | |
| $24.53 | 467 | $11,455.51 | 44,045 | 2025-10-01 | Filing | |
| $24.53 | 373 | $9,149.69 | 116,921 | 2025-10-01 | Filing | |
| $24.63 | 25,000 | $615,667.50 | 986,667 | 2025-10-02 | Filing | |
| $24.51 | 25,000 | $612,655.00 | 986,667 | 2025-10-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,692,853 | $283,785,536 | 0.01% | |
| 2. | 9,250,784 | $224,516,528 | 0% | |
| 3. | 8,148,205 | $197,756,936 | 0% | |
| 4. | 4,830,738 | $117,242,011 | 1.14% | |
| 5. | 4,830,738 | $117,242,011 | 0.07% |
News See All
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
Clear Street Raises PT on Beam Therapeutics (BEAM) to $37 Following Q3 Results
The revised target reflected the company’s robust performance in the third quarter of 2025. The investment firm pointed toward the first patient dosing in Beam Therapeutics Inc.
15 Stocks Set to Explode in 2026
While the market figures out whether artificial intelligence is driving the next bubble or the next industrial revolution, a quiet rotation of capital into the next wave of growth leaders outside Big ...
9 Best Healthcare Stocks with the Highest Upside
Talking about how people are feeling the impact of the shutdown, Dr.
What Does Wall Street Think About Beam Therapeutics (BEAM)?
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best biotech stocks with high potential. H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics Inc.
14 Biotech Stocks with High Potential
Healthcare was the second worst performer this year, with pharma and biotech companies under pressure.
H.C. Wainwright Maintains Buy on Beam (BEAM), $80 Target on Pipeline Momentum
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best emerging technology stocks to buy right now.
11 Best Emerging Technology Stocks to Buy Right Now
While the telephone brought comfort, smartphones changed lives. While factories powered economies, artificial intelligence began rewriting them.
Hedge Fund Resource Center Billionaire Hedge Funds
